1. Lankelma J, van der Klein E, Ramaekers F. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett. 1980; 9:133–142. PMID:
7189691.
Article
2. Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977; 4:87–101. PMID:
329989.
Article
3. Flombaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol. 1999; 17:1589–1594. PMID:
10334548.
Article
4. Relling MV, Stapleton FB, Ochs J, Jones DP, Meyer W, Wainer IW, et al. Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer. 1988; 62:884–888. PMID:
3261621.
Article
5. Kawabata K, Makino H, Nagake Y, Tokioka H, Matsumi M, Morita Y, et al. A case of methotrexate-induced acute renal failure successfully treated with plasma perfusion and sequential hemodialysis. Nephron. 1995; 71:233–234. PMID:
8569964.
6. Minton NP, Atkinson T, Sherwood RF. Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in
Escherichia coli and
Pseudomonas putida. J Bacteriol. 1983; 156:1222–1227. PMID:
6358192.
7. Widemann BC, Sung E, Anderson L, Salzer WL, Balis FM, Monitjo KS, et al. Pharmacokinetics and metabolism of the methotrexate metabolite, 2,4-diamino-N
10-methylpteroic acid. J Pharmacol Exp Ther. 2000; 294:894–901. PMID:
10945838.
8. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982; 49:1221–1230. PMID:
6174200.
9. Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer. 2004; 100:2222–2232. PMID:
15139068.
Article
10. Sohn JH, Rha SY, Jeung HC, Shin HJ, Goo YS, Chung HC, et al. Efficacy of pre- and postoperative chemotherapy in patients with osteosarcoma of the extremities. Cancer Res Treat. 2001; 33:520–526.
Article
11. Kim PS, Ko YH, Jung JE, Kim CW, Cho SG, Kim HK, et al. A case of high dose methotrexate-induced acute renal failure successfully treated with plasma exchange and hemodialysis. Korean J Hematol. 2000; 35:58–61.
12. Greil J, Wyss PA, Ludwig K, Bonakdar S, Scharf J, Beck JD, et al. Continuous plasma resin perfusion for detoxification of methotrexate. Eur J Pediatr. 1997; 156:533–536. PMID:
9243235.
Article
13. Jambou P, Levraut J, Favier C, Ichai C, Milano G, Grimaud D. Removal of methotrexate by continuous venovenous hemodiafiltration. Contrib Nephrol. 1995; 116:48–52. PMID:
8529381.
Article
14. Widemann BC, Balis F, Murphy RF, Sorensen JM, Montello MJ, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol. 1997; 15:2125–2134. PMID:
9164227.
Article